{"id":"dato-dxd","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Interstitial lung disease"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dato-DXd combines a humanized monoclonal antibody against TROP-2 (a tumor-associated antigen) with a topoisomerase I inhibitor payload (deruxtecan). Upon binding to TROP-2 on cancer cells, the conjugate is internalized and the payload is released intracellularly, causing DNA damage and apoptosis. The linker technology allows controlled release of the cytotoxic agent specifically within tumor cells.","oneSentence":"Dato-DXd is an antibody-drug conjugate that targets TROP-2 on cancer cells and delivers a DNA-damaging payload (deruxtecan) to induce cell death.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:45:44.010Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic or unresectable gastric cancer"},{"name":"Metastatic or unresectable biliary tract cancer"},{"name":"Non-small cell lung cancer (NSCLC)"}]},"trialDetails":[{"nctId":"NCT05555732","phase":"PHASE3","title":"Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2023-01-11","conditions":"Metastatic Non Small Cell Lung Cancer","enrollment":1170},{"nctId":"NCT04656652","phase":"PHASE3","title":"Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2020-12-21","conditions":"Non-small Cell Lung Cancer","enrollment":605},{"nctId":"NCT07291037","phase":"PHASE3","title":"Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-10-31","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":400},{"nctId":"NCT05489211","phase":"PHASE2","title":"Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2022-09-06","conditions":"Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer","enrollment":454},{"nctId":"NCT07129993","phase":"PHASE2, PHASE3","title":"Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2025-09-26","conditions":"Urothelial Cancer, Bladder Cancer","enrollment":630},{"nctId":"NCT07205822","phase":"PHASE3","title":"A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-10-30","conditions":"Breast Cancer","enrollment":100},{"nctId":"NCT05629585","phase":"PHASE3","title":"A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-11-28","conditions":"Breast Cancer","enrollment":1174},{"nctId":"NCT06357533","phase":"PHASE3","title":"Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-04-11","conditions":"Non-Small Cell Lung Cancer","enrollment":675},{"nctId":"NCT01042379","phase":"PHASE2","title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2010-03-01","conditions":"Breast Neoplasms, Breast Cancer, Breast Tumors","enrollment":5000},{"nctId":"NCT05687266","phase":"PHASE3","title":"Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-12-29","conditions":"NSCLC","enrollment":1350},{"nctId":"NCT05417594","phase":"PHASE1, PHASE2","title":"Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2022-06-24","conditions":"Advanced Solid Malignancies","enrollment":695},{"nctId":"NCT05460273","phase":"PHASE1, PHASE2","title":"A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-07-11","conditions":"Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Cancer","enrollment":119},{"nctId":"NCT05061550","phase":"PHASE2","title":"Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2022-04-14","conditions":"Non-small Cell Lung Cancer","enrollment":630},{"nctId":"NCT07069595","phase":"PHASE2","title":"PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2026-02-26","conditions":"Breast Cancer, Residual Disease, Triple Negative Breast Cancer (TNBC)","enrollment":78},{"nctId":"NCT06417814","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-10-04","conditions":"Metastatic Non-small Cell Lung Cancer","enrollment":744},{"nctId":"NCT06103864","phase":"PHASE3","title":"A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-11-23","conditions":"Breast Cancer","enrollment":625},{"nctId":"NCT04644068","phase":"PHASE1, PHASE2","title":"Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-11-12","conditions":"Ovarian Cancer, Breast Cancer, Pancreatic Cancer","enrollment":702},{"nctId":"NCT07098338","phase":"PHASE2","title":"A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-08-07","conditions":"Non-Small Cell Lung Cancer","enrollment":278},{"nctId":"NCT06244485","phase":"PHASE1","title":"A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2024-02-16","conditions":"Advanced Solid Tumor","enrollment":210},{"nctId":"NCT05104866","phase":"PHASE3","title":"A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-10-18","conditions":"Breast Cancer","enrollment":732},{"nctId":"NCT03742102","phase":"PHASE1, PHASE2","title":"A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-12-21","conditions":"Triple Negative Breast Neoplasms","enrollment":243},{"nctId":"NCT06564844","phase":"PHASE3","title":"A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-10-15","conditions":"Non-small Cell Lung Cancer","enrollment":24},{"nctId":"NCT05374512","phase":"PHASE3","title":"A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-05-16","conditions":"Breast Cancer","enrollment":644},{"nctId":"NCT07357597","phase":"PHASE4","title":"An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.","status":"NOT_YET_RECRUITING","sponsor":"AstraZeneca","startDate":"2026-02-27","conditions":"Stomatitis","enrollment":100},{"nctId":"NCT05215340","phase":"PHASE3","title":"Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2022-03-04","conditions":"Metastatic Non Small Cell Lung Cancer","enrollment":740},{"nctId":"NCT04612751","phase":"PHASE1","title":"Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-02-02","conditions":"Advanced or Metastatic NSCLC","enrollment":155},{"nctId":"NCT06112379","phase":"PHASE3","title":"A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-11-14","conditions":"Breast Cancer","enrollment":1902},{"nctId":"NCT04940325","phase":"PHASE2","title":"Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2021-05-12","conditions":"Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer, Unresectable Non-small Lung Cancer","enrollment":100},{"nctId":"NCT05117476","phase":"PHASE1","title":"A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cullinan Therapeutics Inc.","startDate":"2021-10-29","conditions":"Advanced Solid Tumor, NSCLC","enrollment":440},{"nctId":"NCT06954480","phase":"PHASE2","title":"Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer","status":"RECRUITING","sponsor":"Queen Mary University of London","startDate":"2025-10-27","conditions":"Triple Negative Breast Cancer","enrollment":140},{"nctId":"NCT06350097","phase":"PHASE3","title":"Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-04-29","conditions":"Non-small Cell Lung Cancer","enrollment":582},{"nctId":"NCT06974604","phase":"PHASE2","title":"Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM","status":"RECRUITING","sponsor":"Brown University","startDate":"2025-10-22","conditions":"Breast Neoplasms, Lung Neoplasms","enrollment":60},{"nctId":"NCT06533826","phase":"PHASE2","title":"TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd","status":"RECRUITING","sponsor":"Ana C Garrido-Castro, MD","startDate":"2024-10-29","conditions":"Breast Cancer, HER2-low Breast Cancer, Metastatic Breast Cancer","enrollment":357},{"nctId":"NCT03401385","phase":"PHASE1","title":"First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2018-01-31","conditions":"Hormone Receptor Positive Breast Cancer, Triple Negative Breast Cancer, Non-small Cell Lung Cancer","enrollment":890},{"nctId":"NCT06822543","phase":"PHASE2","title":"A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)","status":"RECRUITING","sponsor":"Latin American Cooperative Oncology Group","startDate":"2025-09-30","conditions":"Lung Cancer, Non Small Cell Lung Cancer, Brain Metastases","enrollment":46},{"nctId":"NCT05866432","phase":"PHASE2","title":"Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2023-07-01","conditions":"Breast Cancer Stage IV","enrollment":20},{"nctId":"NCT06676917","phase":"PHASE2","title":"Datopotamab Deruxtecan (Dato-DXd) for Non-Small Cell Lung Cancer (NSCLC) Patients With Active Brain Metastases","status":"WITHDRAWN","sponsor":"MedSIR","startDate":"2025-06","conditions":"Non-small Cell Lung Cancer","enrollment":""},{"nctId":"NCT06176261","phase":"PHASE2","title":"DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs","status":"RECRUITING","sponsor":"Sarah Sammons, MD","startDate":"2024-01-08","conditions":"Breast Cancer, Breast Cancer Female, Metastatic Triple-Negative Breast Carcinoma","enrollment":58},{"nctId":"NCT06279728","phase":"","title":"Medical Access Program for Datopotamab Deruxtecan in EGFRm NSCLC Patients","status":"APPROVED_FOR_MARKETING","sponsor":"Daiichi Sankyo","startDate":"","conditions":"EGFRm Advanced Non-Small Cell Lung Cancer, EGFRm Metastatic Non-Small Cell Lung Cancer","enrollment":""},{"nctId":"NCT04526691","phase":"PHASE1","title":"Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2020-09-15","conditions":"Advanced or Metastatic NSCLC","enrollment":145},{"nctId":"NCT06508216","phase":"PHASE1, PHASE2","title":"A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2024-07-05","conditions":"Breast Cancer","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":75,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["DS-1062a","Datopotamab deruxtecan (Dato-DXd, DS-1062a)","Datopotamab Deruxtecan","IMP administration","DS-1062"],"phase":"phase_3","status":"active","brandName":"Dato-DXd","genericName":"Dato-DXd","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dato-DXd is an antibody-drug conjugate that targets TROP-2 on cancer cells and delivers a DNA-damaging payload (deruxtecan) to induce cell death. Used for Metastatic or unresectable gastric cancer, Metastatic or unresectable biliary tract cancer, Non-small cell lung cancer (NSCLC).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":4,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}